Short-Course Radiotherapy Combined with Intracavitary Brachytherapy Followed by Pucotenlimab, Bevacizumab, Oxaliplatin, and Trifluridine/Tipiracil (TAS-102) for Total Neoadjuvant Therapy of Microsatellite Stable (MSS) Locally Advanced Low Rectal Cancer

Launched by SIR RUN RUN SHAW HOSPITAL · Mar 10, 2025

Keywords

ClinConnect Summary

This clinical trial is exploring a new treatment approach for patients with locally advanced low rectal cancer. The study aims to see how effective a combination of short-term radiation therapy and several medications—including Pucotenlimab, Bevacizumab, Oxaliplatin, and Trifluridine/Tipiracil—can be in shrinking the tumor and preserving the rectum before surgery. Researchers will look closely at how well the treatment works and monitor the patients' overall health and quality of life.

To participate in the trial, patients must be at least 18 years old, have a specific type of rectal cancer that is less than 5 cm from the anus, and meet some health criteria to ensure they can safely undergo the treatment. Participants can expect regular monitoring throughout the study, and they'll be contributing to important research that could help improve treatment options for others in the future. It's important to note that this trial is not yet recruiting participants, but it could be a valuable opportunity for eligible patients once it begins.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • 1. Patients who are willing to receive neoadjuvant therapy.
• • 2. ≧18 years old.
• • 3. Diagnosed by digital rectal examination, colonoscopy, and high-resolution MRI of the pelvis, the tumor is less than or equal to 5 cm from the anus.
• • 4. Histologically diagnosed as rectal adenocarcinoma.
• • 5. Clinical stage: cT2-4a N+ or cT3/T4a N0 (MRI/CT-confirmed).
• • 6. MSS/pMMR status confirmed by immunohistochemistry or PCR before treatment .
• • 7. ECOG Scale of Performance Status score 0-1 point.
• • 8. Adequate organ function (hematologic, hepatic, renal).
• • 9. Have not received anti-tumor and immunotherapy before enrollment.
• 10. Laboratory inspections must meet the following standards:
• • 1) White blood cell count\>3.5×109/L, absolute value of neutrophils\>1.8×109/L, platelet count ≥75×109/L, hemoglobin ≥100g/L; 2) INR≤1.5, and APTT≤1.5 times the upper limit of normal or partial prothrombin time (PT) ≤1.5 times the upper limit of normal; 3) Total bilirubin ≤ 1.25 times the upper limit of normal; ALT and AST \< 5 times the upper limit of normal; 4) 24h creatinine clearance \>50mL/min or serum creatinine \<1.5 times the upper limit of normal.
• • 11. Voluntarily participate in this study and sign the informed consent.
• Exclusion Criteria:
• • 1. History of other malignant diseases in the past 5 years.
• • 2. Patients with metastases from other sites (stage IV patients).
• • 3. Patients withT4b or positive lateral lymph nodes by pelvic contrast-enhanced CT and pelvic high-resolution MRI.
• • 4. Patients with intestinal obstruction, intestinal perforation, intestinal bleeding, etc. requiring emergency surgery.
• • 5. Known allergic to oxaliplatin, PD-1 monoclonal antibody and other intervention drugs.
• • 6. Pathologically suggested signet ring cell carcinoma and mucinous adenocarcinoma.
• • 7. dMMR or MSI-H patients.
• • 8. The patient is accompanied by any unstable systemic disease, including but not limited to: severe infection, uncontrolled diabetes, hypertension uncontrolled by medication, unstable angina, cerebrovascular accident or transient cerebral ischemia, myocardial Infarction, congestive heart failure, severe cardiac arrhythmia requiring medication, hepatic, renal or metabolic disease; disease affecting the patient's life.
• • 9. The disease (such as mental illness, etc.) or condition (such as alcoholism or drug abuse, etc.) associated with the patient will increase the risk of the patient receiving the trial drug treatment or affect the patient's compliance with the trial requirements, or may confuse the research results.
• • 10. Active autoimmune disease that may worsen while receiving immunostimulants.
• • 11. Known history of positive HIV test or known acquired immunodeficiency syndrome.
• 12. Patients who are using immunosuppressive agents, except for the following conditions:
• • 1) Intranasal, inhaled, topical steroids, or topical steroid injections (eg, intra-articular injections); 2) Physiological doses of systemic corticosteroids ≤10 mg/day prednisone or equivalent; 3) Steroids used to prevent allergic reactions (eg, before CT scan). 13. Received any other experimental drug treatment or participated in another interventional clinical trial within 30 days before screening 14. Women who are pregnant or breastfeeding or who plan to become pregnant or breastfeeding during the study period; men or women who are unwilling to take effective contraceptive measures.
• • 15. Vulnerable groups, including mentally ill, cognitively impaired, critically ill patients, minors, etc.
• • 16. Other conditions that the investigator judges that the patient is not suitable to participate in the clinical study, etc.